Ironwood Pharmaceuticals Inc
Latest Ironwood Pharmaceuticals Inc News and Updates
Here’s What Tesaro’s Valuation Trend Indicates
Tesaro stock has been on a downward trajectory for the past 52 weeks. From a high of $135 on September 5, 2017, it has corrected to $27 in August.
What Does Nektar Therapeutics’ Valuation Trend Indicate?
Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).
The Financial Performance of Sucampo Pharmaceuticals
Sucampo Pharmaceuticals (SCMP) generated revenues of $61.2 million in 3Q17 compared with $57 million in 3Q16.
Sucampo Pharmaceuticals’ Amitiza: Its Competitive Landscape
In the branded prescription category, Amitiza competes with Ironwood Pharmaceuticals (IRWD) and Allergan’s (AGN) Linzess.
AstraZeneca’s Recent Products: Approvals and Designations
AstraZeneca’s (AZN) recent product developments include four drugs that have recently received approvals from regulatory authorities. Four other drugs have received regulatory designations.
Will AstraZeneca’s Corporate Developments Help?
In this part, we’ll look at some of AstraZeneca’s corporate developments. It entered into some collaborative agreements in 1Q16, including drug development and commercialization rights.
IBB Small-Caps Reduce Negative Returns in December
The small-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) rose 1.4% on December 21, 2015, and reduced the negative returns.
